RLS Global AB (publ)
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RLS.ST research report →
Companyrls.global
RLS Global AB (publ), a medical technology company, develops and sells products for the treatment of illnesses in wound and oral care in Sweden. Its products include ChloraSolv that is used for the treatment of chronic diabetic foot and leg ulcers for diabetic patients; and CariSolv, a gel used for removing caries. The company was founded in 1996 and is based in Mölndal, Sweden.
- CEO
- Roland Frosing
- IPO
- 2005
- Employees
- 9
- HQ
- Mölndal, SE
Price Chart
Valuation
- Market Cap
- $35.70M
- P/E
- -1.27
- P/S
- 29.80
- P/B
- 0.96
- EV/EBITDA
- -0.68
- Div Yield
- 0.00%
Profitability
- Gross Margin
- -34.31%
- Op Margin
- -2034.06%
- Net Margin
- -2033.97%
- ROE
- -93.85%
- ROIC
- -76.04%
Growth & Income
- Revenue
- $1.20M · 83.46%
- Net Income
- $-24,367,000 · -112.68%
- EPS
- $-0.35 · -105.88%
- Op Income
- $-24,368,000
- FCF YoY
- -230.46%
Performance & Tape
- 52W High
- $0.45
- 52W Low
- $0.45
- 50D MA
- $0.45
- 200D MA
- $0.45
- Beta
- 0.57
- Avg Volume
- 0
Get TickerSpark's AI analysis on RLS.ST
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our RLS.ST Coverage
We haven't published any research on RLS.ST yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate RLS.ST Report →